【4565】そーせいG 460 【Novartis Q3 Results 2018: 10/18】

空売り外資に勝てるわけないやろw

動画で言ってた豊富なパイプラインのIRに期待する。

これまで良好な結果がでていたこと、予期せぬ事態となったこと、今回の毒性と薬との因果関係を特定するのにはとても時間がかかると思う。

>>147
呼んだ?
2000程溶かしたがコイン関連で増やした分だから収支でいえば大幅に+

田村はほとんど株持ってないよ。２万以上で利確。

そーせいのチャート緑一色狙ってるのかな

安値引けw

(;o;)

垂れ乳だろうがプリプリ乳だろうが乳チャートというものはＷ形チャートだから
最後は上がるはずなんだが

※SOSEI定時株主総会：「当社事業の飛躍的な拡大」：COPDフランチャイズ売上は順調推移・複数の共同開発プログラム保有・自社PLの迅速な拡充。日本から世界へ：新たなグローバルブランド(“Sosei Heptares”)へ統一：2018年内に運用開始。(6/22)
※Heptares: Changed to “Heptares is Based the New Research Facility (Steinmetz Building) of Granta Park (Cambridge) from August 2018”. (7/9up)
・The company is currently based in Welwyn Garden City; however, this role will be based at our brand-new research facility at Granta Park (Cambridge) from August 2018.
※Granta Park_HP: Complete Refurbishment of the Steinmetz Building for Heptares. (8/1)
※Miles Congreve (Heptares): My last day at BioPark (ttps://pbs.twimg.com/media/DjnXjo0X0AA2Ggq.jpg). bring on Granta Park, Cambridge! (8/2)
※Heptares_Twitter (Change Name): Heptares→”SoseiHeptares”. (8/6 Changed)
※Heptares_HP: Changed Contact: Heptares Therapeutics Ltd. BioPark, Broadwater Road, Welwyn Garden City, Hertfordshire, AL7 3AX, UK.→”Heptares Therapeutics Ltd. “Steinmetz Building, Granta Park, Great Abington, Cambridge, CB21 6DG, UK.” (9/8update)
※Heptares Host Event up: Cambridge New Therapeutics Forum (CamNTF) February Meeting (2019/2/13 18:00-20:00, Location: Granta Park): Richard Henderson, MRC LMB (18:10 Presenting), Stacey Southall, “Sosei Heptares” (18:55 Presenting). (9/20up, 10/6update)
※Granta Park: Registration is now open for this years Santa Run at Granta Park. (ttps://pbs.twimg.com/media/DovrzfhXsAAp5KM.jpg): Left Building (“Steinmetz Building, SoseiHeptares”). (10/5)
※Granta Park: Everyone is enjoying the atmosphere as the 10k runners continue to come in family day out. (ttps://pbs.twimg.com/media/Do5ixDaWwAIppik.jpg): Center Building(“Steinmetz Building, SoseiHeptares”). (10/7)

カニ食いザルが大笑い！

馬鹿しかいない

いったい何を希望に長期ホールドすれば良いのだろうか

ＰＴＡ

おはよう！　カニ食いザルさん！

３連休前の金曜日。　どーーーん　と行ってみよう。

五味さんここ最近の行ってこいで他の株売ってそーせいに全力二階建てしてたりしてな

言わんこっちゃない

マイ転くるううううううううう

悲観で買えと言うじゃないですか。さぁさぁ、買った買った!

Pluristem:
・・・
※Pluristem: Company Presentation July 2018. Critical Limb Ischemia (CLI): PLX-PAD: Single pivotal study (Japan). Collaboration with Fukushima Medical University: Evaluating PLX-R18 cells as a treatment for radiation damage to the gastrointestinal (GI) tract and bone marrow. (7/23update)
※Pluristem: “New patent in Japan- covers PLX-R18’s protection of the gastrointestinal (GI) tract from radiation exposure”. Recent data from Fukushima University shows PLX-R18 cells significantly increased survival and enhanced the recovery of the GI tract after radiation exposure (7/26)
※Pluristem Initiates Two Pivotal Phase III Studies in Israel. “Numerous Clinical Sites in Israel to join sites in the U.S. and Europe for Pivotal Phase III Studies of PLX-PAD Cell Therapy in the Treatment of Critical Limb Ischemia and Muscle Injury Following Hip Fracture”(8/8)
※Pluristem: “Last dat for the 2018 MHSRS Conference- Arik Eisenkraft, MD, MHA, Director of Homeland Defense Projects, at the Gaylord Palms Resort & Convention Center, Kissimmee, FL. Glad to attend and share data with U.S. and other international colleagues”. (8/23)
※Pluristem: “Does the Placenta Hold the Answer to One of Our Most Challenging Medical Problems? (Bloomberg)” (9/12up)
※Pluristem: FY 2018 Earnings: “SEC Filing: Annual Report”: Sosei CVC for commercialization of our PLX-PAD cell therapy product in Japan for CLI: We are still in discussions with Sosei CVC and other related investors in order to finalize the terms of a definitive agreement. (9/12)
※Pluristem: FY 2018 Earnings: “Financial Statements: FY 2018 (Fiscal Year Ended June 30, 2018)”. ttps://www.pluristem.com/wp-content/uploads/2018/09/PSTI_10K_June_30_2018_isa.pdf (9/13up)
※Pluristem: “Does the Placenta Hold the Answer to One of Our Most Challenging Medical Problems? (Bloomberg)”: PAD Awareness Month: “We are proud to lead the most promising solution for this serious medical roblem.” (9/13)
※Pluristem: “IRMC patient receives historic stem cell surgery” (The Indiana Gazette). A first for American medicine may have occurred on Sept. 12 at the Indiana Regional Medical Center. (9/23).
※Pluristem Therapeutics receives FDA orphan status for treatment of graft failure and incomplete hematopoietic recovery, following hematopoietic cell transplantation (HCT). (9/24)
※Pluristem Therapeutics Announces FDA Orphan Drug Designation for PLX cell therapy for the Treatment of Graft Failure and Incomplete Recovery Following Hematopoietic Cell Transplantation. (9/25)
※Pluristem Reports Fiscal 2018 Fourth Quarter Results and Provides Corporate Update. “September is Peripheral Artery Disease (PAD) awareness month.” (9/27)
※Pluristem: Lior Raviv, VP Development at Pluristem, for BWB TV at Biotech Week Boston- discusses the importance of process development and automation to the future of cell therapy manufacturing, as well as the potential of 3D production. Interview: “Cell therapy today is more of an art than a process” (9/30)
※Cell & Gene Therapy, London: “Becoming Cell Therapy Makers – Opportunities and Challenges in “in House” Manufacturing of Cell Therapy Products”: Lior Raviv, Vice President of Development, Pluristem. (10/10 Presented)
※Pluristem Therapeutics Announces Publication in JCSM of Two-Year Follow-Up Data from Phase I/II Study in Muscle Regeneration and European Clearance for Ongoing Phase III Study. PLX-PAD cells Demonstrated a Significant Increase in Muscle Volume and Strength. (10/10)
↓

ビックニュース　第三者割当増資　増資しかできないそーせいヘプタレス　ヘプタレスリストラしろよ

気配 大 暴 落

売りたい人しか居ないらしいぞ

フェーズが何の事を言っているのか判らんが色々進捗も提携もあったよ

ピータズペイン

※MiNA Therapeutics: “Senior Translational Scientist”: “Looking for a top Translational Scientist to help drive development of transformational RNA medicines” (Expires: 2018/10/19). MiNA’s first clinical asset has successfully completed Phase 1 and MiNA is developing a pipeline. (8/20)
※MiNA Therapeutics_HP: New Video: “MiNA Therapeutics – RNA Activation” (ttp://minatx.com/rna-activation/#rna_section_two_video). (8/22up) ※MiNA Therapeutics: Check out our new video explaining how saRNA medicines work. (8/28)
※ClinicalTrials: Phase 1/2a, First-in-Human Safety and Tolerability Study of MTL-CEBPA in Patients With Advanced Liver Cancer (OUTREACH): Phase 2a Study Status Change: Primary Completion: 2018/9→”2019/3″, Study Completion: 2018/12→”2019/12″. (9/10update)
※米国特許出願(MiNA)：”Sarna Compositions and Methods of Use”. (9/13公開)
※ILCA 2018: “First-in-Human, First-in-Class Phase I Study of MTL-CEBPA, a Small Activating RNA (saRNA) Targeting the Transcription Factor C/EBP-α inPatients with Advanced Liver Cancer” Debashis Sarker, Support from MiNA Therapeutics. (9/16 11:45 Presented)
・Conclusion: MTL-CEBPA therapy was well tolerated, shows evidence of target engagement and initial clinical responses in patients with advanced HCC. Updated results for the dose escalation will be presented. Clinical trial information: NCT02716012.
※MiNA Therapeutics: Announces Findings From MTL-CEBPA Clinical Trial in Patients with Advanced Liver Cancer at International Liver Cancer Association Conference. (9/19)
※SOSEI：「MiNA Therapeutics社が進行肝がん患者を対象にした小分子活性化RNA肝がん治療候補薬MTL-CEBPAの臨床試験についての最新情報を国際肝癌研究会(ILCA)年次総会で発表」。(9/19)
・MTL-CEBPA(小分子活性化RNA(saRNA)候補薬)の臨床試験終了後に、引き続き標準的治療を適応した患者において完全奏功が認められたことを治験責任医師が口頭発表。腫瘍微小環境でのCEBPAの役割に対する新たな知見により、新たな療法の可能性を評価する機会が生み出されました。
・進行肝がんを対象とした標準治療薬とMTL-CEBPAとの併用治療を臨床的に評価するために現在進行中の臨床試験実施計画を修正する予定。進行中の第相試験にMTL-CEBPAの併用試験を追加実施すべく規制当局と鋭意協議。ソラフェニブ併用での試験は2018年第4四半期に開始される予定。
※欧州特許(MiNA)：Albumin Production and Cell Proliferation. (9/19公開)
※個別株情報：みずほ証券では引き続き成長余地は大きいとみる。最大の注目点は10月中旬〜後半にかけて、MiNA社の買収オプション権を行使するか否かである。MTL-CEBPAのPhase1/2a試験を進めており、試験結果が良好であれば買収を行い、カタリストにもなると指摘。(9/27)

眠たい動きやなドカンと買えや

こんな株長期で持つとか正気じゃない
筆頭株主が個人でしかも大損してる時点でもうだめだろ
赤字企業なのに金遣いが荒いから案外つぶれるのも早いのかもな

賢明な経営判断だな

とりあえず手持ちの現金が200億円以上あるし、株価下落に対して、田村もピーターも何も思ってないんだろうな・・

100万株買う金持ちはおらんのか

また上がるとすぐ叩き落とす、どんなリバもすべて潰してる

腫瘍ねぇ…神経が発達しまくって神経節にでもなったか

Ｍ4はサル実験は大丈夫らしいが、速報っていつ分かる？
そろそろだよな

1030で安心感あたえてからの500円コースでしょ

Heptares Patent update:
・・・
※日本特許(Heptares)：4‐(3‐シアノフェニル)‐6‐ピリジニルピリミジンMGLU5修飾剤【特許6346666】。(6/1公開)
※米国特許出願(Heptares)：CGRP Receptor Antagonists (US20180153876A1). (6/7公開)
※米国特許出願(Heptares)：Muscarinic M1 Receptor Agonists. (6/7公開)
※米国特許出願(Heptares)：Muscarinic Agonists (US20180155315A1). (6/7公開)
※欧州特許出願(Heptares)：Muscarinic Agonists (EP3331528 A1 EP3331529 A1 EP3331869 A1). (6/13公開)
※欧州特許出願(Heptares)：Mutant GPCRS. (6/13公開)
※欧州特許(Heptares)：Bicyclic AZA Compounds as Muscarinic M1 Receptor Agonists. (6/27公開)
※米国特許出願(Heptares)：Bicyclic AZA Compounds as Muscarinic M1 Receptor and/or M4 Receptor Agonists. (6/28公開)
※日本商標出願(Heptares)：MATILDA【出願番号】商願2018-79942。(7/3公開)
※米国特許(Heptares)：Piperidin-1-YL and Azepin-1-YL Carboxylates as Muscarinic M4 Receptor Agonists (Inventors: Takeda Cambridge & Heptares Therapeutics) (7/24公開)
※米国特許(Heptares)：Muscarinic Receptor Agonists. (7/24公開)
※米国特許出願(Heptares)：Muscarinic Agonists (US20180222885A1). (8/9公開)
※米国特許出願(Heptares)：Muscarinic Agonists (US20180228791A1). (8/16公開)
※欧州特許(Heptares)：Piperidin-1-YL and Azepin-1-YL Carboxylates as Muscarinic M4 Receptor Agonists (Inventors: Takeda Cambridge & Heptares Therapeutics). (8/22公開)
※日本特許出願(Heptares)：「オレキシン受容体アンタゴニスト」(8/30公開)
※欧州特許出願(Heptares)：CGRP Receptor Antagonists (EP3368525A1, EP3368526A1, EP3368536A1). (9/5公開)
※欧州特許出願(Heptares)：Oxime Compounds as Agonists of the Muscarinic M1 Receptor and/or M4 Receptor Agonists. (9/12公開)
※米国特許出願(Heptares)：Bicyclic AZA Compounds as Muscarinic M1 Receptor Agonists. (9/13公開)
※欧州特許(Heptares)：4-(3-Cyanophenyl)-6-Pyridinylpyrimidine mGLU5 Modulators. (9/26公開)
↓
※国際特許出願(Heptares)：”CGRP Receptor Antagonists”. (10/4公開)
・Document Type and Number: WIPO Patent Application WO/2018/178938 A1
・Publication Date: 2018/10/4
・Assignee: Heptares Therapeutics Limited
Abstract:
The disclosures herein relate to novel compounds of formula (IA) wherein R1, R2, R3 and R4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.
The disclosures herein also relates to novel compounds of formula(IB) wherein R1, R2 and R3 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.
The disclosures herein also relate to novel compounds of formula (IC) wherein Ar1 and R1 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.

成功を織り込んでない株価なら次また腫瘍出来ても下がるわけないお

はやく売らなきゃ大変な事になりそう。

※Chris de Graaf (Heptares) 3時間前：”A minergic GPCR-Ligand Interactions: A Chemical and Structural Map of Receptor Mutation Data.” (10/17)

※Journal of Medicinal Chemistry: “Aminergic GPCR-Ligand Interactions: A Chemical and Structural Map of Receptor Mutation Data.” (10/17 Publicated)
(Marton Vass, Sabina Podlewska, Iwan J. P. De Esch, Andrzej J. Bojarski, Rob Leurs, Albert J. Kooistra, and Chris de Graaf) 3D-e-Chem NLeSC project
Publication Date (Web): October 17, 2018
Abstract
The aminergic family of G protein-coupled receptors (GPCRs) plays an important role in various diseases and represents a major drug discovery target class.
Structure determination of all major aminergic subfamilies has enabled structure-based ligand design for these receptors.
Site-directed mutagenesis data provides an invaluable complementary source of information for elucidating the structural determinants of binding of different ligand chemotypes.
The current study provides a comparative analysis of 6692 mutation data points on 34 aminergic GPCR subtypes, covering the chemical space of 540 unique ligands from mutagenesis experiments,
and information from experimentally determined structures of 52 distinct aminergic receptor-ligand complexes.
The integrated analysis enables detailed investigation of structural receptor-ligand interactions and assessment of the transferability of combined binding mode and mutation data across ligand chemotypes and receptor subtypes.
An overview is provided of the possibilities and limitations of using mutation data to guide the design of novel aminergic receptor ligands.

五味さん自暴自棄にならなきゃいいが

全財産で買え

ここのホルダーみんな頭おかしくなってるなw
現実が見えないw

マジで2000円で買収されてくれ・・
それでも五味やタイヨウは含み損だけど我慢しろ
それしか俺たちが助かる道はねえ

バーカ

地合良い時に押さえつけておけばあとは勝手にさがるだけ
空売り外資楽勝やろな

悪材料10連発もあり得る
そんだけ弱気

不祥事の１つでもしたほうが株価は高くなるかもな

倒産して初めて許されるんだよ

※技術情報協会ペプチドスケールアップセミナー：「ペプチド原薬の化学合成技術とスケールアップ」JITSUBO(株) 研究開発部 部長 山崎貴史。(10/23 10:00〜12:00)
※Schrodinger Life Science User Meeting 2018, Boston: keynote “SBDD finally come of age: R(eal)I drives rational design, including FEP on GPCRs, with waters found key for binding, selectivity and kinetics – a 35 year perspective”: Jon Mason, Heptares. (10/23 9:15 Presenting)
※New York Area Group for Informatics and Modeling (NYAGIM) Event: “4 Decades of CADD in Pharma: A personal perspective of critical lessons learned from each decade that will enhance our ability to succeed in the future” Jon Mason, Heptares. (10/30 18:00 Presenting)
※BIO-Europe, Copenhagen, Denmark: Company Presentations, MiNA Therapeutics. (11/5-7 Presenting)
※AASLD Liver Meeting 2018, San Francisco: MiNA Therapeutics. (11/9-13)
※Jefferies London Healthcare Conference, London, UK: MiNA Therapeutics. (11/14-15)
※PSDI 2018 (26th Protein Structure Determination in Industry Meeting”), Versailles: Keynote Speaker: “A Decade of GPCR Structure-Based Drug Design – Structural insights into the allosteric control of GPCR activity”: Dr. Andrew S. Dore, Heptares. (11/11 21:00 Presenting)
※PCT: Partnerships in Clinical Trials Europe: “Use of molecular and functional Imaging in early clinical development: From target engagement to proof of concept”: Pradeep Nathan, Vice President, CNS Clinical Development and Experimental Medicine at Heptares. (11/28 16:00 Presenting)
※PREP UK 2018: Organising Committee: Kerry O’Hare, Lead Analytical and Purification Chemist, Heptares. (11/29-30)
・”Implementation of MP infrastructure at Heptares”: Kerry O’Hare, Heptares. (11/29 11:55 Presenting) ※10/6up
・”Session 3 – New Tricks”: Chair: Kerry O’Hare. (11/29 15:45 Session Chair) ※10/6up
・”Chrom Logd as part of compound management workflow”: Kerry O’Hare, Heptares. (11/30 10:05 Presenting) ※10/6up
・・・
※Cambridge New Therapeutics Forum (CamNTF) February Meeting (2019/2/13 18:00-20:00) (Host: Heptares. Location: Granta Park): Richard Henderson, MRC LMB (18:10 Presenting), Stacey Southall, “Sosei-Heptares”. (18:55 Presenting) ※10/6update
※SMi’s 10th Annual RNA Therapeutics Returns to London This February 2019: ”Small Activating RNA – from Bench to Bedside”: David Blakey, Chief Scientific Officer, MiNA Therapeutics. (2019/2/21 13:40 Presenting)
・・・

ガンガン買えや

ダウん